GLP-1 and Wound Healing: The Evidence (2026)

If you take Ozempic, Wegovy, Mounjaro or Zepbound and you have surgery — or just a cut that won't close — coming up, you may have read that GLP-1 drugs “impair wound healing.” Here is the honest picture: there is no strong human evidence that GLP-1 receptor agonists slow surgical wound healing. The concern is almost entirely theoretical, and it rests on a real but indirect mechanism — these drugs cause weight loss that includes some lean (muscle) tissue, and they suppress appetite, which can drop protein intake below what tissue repair needs (Neeland 2024 ^[8]; Wilding 2021 ^[7]). Wound healing is protein-hungry, so in theory under-fueling it could matter. But when researchers have actually looked at GLP-1 drugs in skin and wound models, the surprise is that the results lean the other way: in lab and animal studies these drugs tend to be anti-inflammatory and pro-angiogenic (they help build new blood vessels), and several accelerate healing rather than slow it (Ghebrehiwet-Kuflom 2025 ^[1]; Nagae 2018 ^[2]; Huang 2021 ^[3]). This article separates the mechanistic worry from the actual data. For the closely related questions, see GLP-1s and cosmetic-surgery recovery and holding a GLP-1 before surgery.

The honest summary

• No human trial shows GLP-1s impair wound healing. The clean answer most people are looking for: there is no randomized controlled trial in people showing that semaglutide, tirzepatide or any GLP-1 slows surgical or skin wound closure. The concern is mechanistic and theoretical (Ghebrehiwet-Kuflom 2025^[1]).
• The real mechanism is indirect — it's about fuel, not the drug itself. GLP-1 weight loss includes some lean mass, and reduced appetite can drop protein intake. Tissue repair needs protein. So the plausible risk is under-nutrition during healing, not a direct toxic effect on the wound (Neeland 2024^[8]; Wilding 2021^[7]).
• Lab and animal data are mostly reassuring — even beneficial. In keratinocytes, liraglutide sped up cell migration via the PI3K/Akt pathway (Nagae 2018^[2]). In diabetic mice it accelerated wound closure by improving blood-vessel function (Huang 2021^[3]) and boosted ischemia-driven new-vessel growth (Zhu 2023^[5]). Exendin-4 (a GLP-1) improved diabetic wound healing in mice (Seo 2017^[4]).
• Human diabetes data point toward fewer limb complications, not more. In the large LEADER cardiovascular trial, liraglutide did not raise diabetic-foot-ulcer events and was linked to a significantly lower risk of ulcer-related amputations versus placebo (Dhatariya 2018^[6]).
• So why the worry at all? Because healing is catabolically demanding and rapid weight loss with low protein intake is a known risk factor for poor surgical recovery (Weimann 2017^[9]; Weimann 2024^[10]). The drug doesn't poison the wound — but starving the patient of protein during recovery can.
• Bottom line: focus on protein, not panic. The actionable lesson isn't “GLP-1s are dangerous for wounds” — it's “protect your protein intake and muscle around any healing event,” and coordinate perioperative plans with your team.

Why people think GLP-1s might impair healing

The concern is a chain of reasonable inferences, not a measured outcome. First, GLP-1 receptor agonists produce large weight loss — in STEP 1, semaglutide 2.4 mg dropped body weight about 14.9% over 68 weeks versus 2.4% on placebo (Wilding 2021^[7]). Second, a meaningful share of that weight is lean mass, not just fat. Across GLP-1-based therapies, lean tissue typically accounts for a substantial fraction of total weight lost — often in the range of a quarter to 40% depending on the study and how it's measured (Neeland 2024^[8]). Third, these drugs work partly by suppressing appetite, so people eat less overall — including less protein.

Now layer wound healing on top. Repairing tissue is an anabolic, protein-intensive process: the body needs amino acids to build collagen, immune cells, and new tissue. Surgical and clinical-nutrition guidelines have long flagged that under-nutrition — and protein under-feeding in particular — is associated with worse surgical outcomes, including wound complications and delayed recovery, which is why they push higher protein intake around surgery (Weimann 2017^[9]; Weimann 2024^[10]). Put those together and you get the theoretical worry: a person losing weight fast on a GLP-1, eating little, and shedding some muscle might not have the protein “budget” a healing wound demands. That is a coherent hypothesis. What it is not is a demonstrated effect of the drug on the wound itself.

What the preclinical (lab and animal) data actually show

Here is where the story gets counterintuitive. When scientists test GLP-1 drugs directly on skin cells and on wounds in animals, the drugs generally help. A 2025 narrative review in the Journal of Investigative Dermatology pulled this literature together and described GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic cutaneous wound healing — summarizing mechanistic pathways through which they may dampen pro-inflammatory signaling, push macrophages toward a pro-repair (M2) phenotype, and promote new blood-vessel growth that wounds need to close (Ghebrehiwet-Kuflom 2025^[1]).

The individual studies behind that conclusion are fairly consistent. In cultured human keratinocytes — the skin cells that re-cover a wound — the GLP-1 analogue liraglutide facilitated wound healing by activating the PI3K/Akt pathway, speeding cell migration (Nagae 2018^[2]). In diabetic mice, liraglutide promoted wound healing by preventing endothelial dysfunction via AMPK–HIF-1α–heme-oxygenase-1 signaling — essentially keeping the wound's blood supply healthier (Huang 2021^[3]). A separate murine study found liraglutide accelerated ischemia-induced angiogenesis (new-vessel growth) in a diabetic model, improving perfusion and capillary density (Zhu 2023^[5]). And exendin-4, another GLP-1, improved diabetic wound healing in mice, with even better results when combined with stem cells (Seo 2017^[4]).

What the human data show: diabetic and surgical wounds

The most relevant human evidence comes from diabetes, where wound problems — especially diabetic foot ulcers — are common and well-tracked. In the LEADER trial, a large cardiovascular-outcomes study of liraglutide in people with type 2 diabetes at high cardiovascular risk, liraglutide did not increase diabetic-foot-ulcer events and was associated with a significantly lower risk of ulcer-related lower-extremity amputations compared with placebo (Dhatariya 2018^[6]). That is a reassuring real-world signal: if the drug meaningfully sabotaged wound healing, you would not expect fewer amputations.

What is genuinely missing is a head-to-head randomized trial measuring surgical wound healing — say, time to closure or rate of wound dehiscence — in people on a weight-loss-dose GLP-1 versus those not on one. As of 2026 that trial does not exist. So claims in either direction (“impairs healing” or “speeds healing”) outrun the human surgical evidence. The defensible statement is narrow: there is no human evidence that GLP-1 drugs impair surgical wound healing, and the available human diabetes data and preclinical data trend reassuring (Ghebrehiwet-Kuflom 2025^[1]; Dhatariya 2018^[6]).

The lever that actually matters: protein and muscle

If the drug isn't the villain, what should you focus on? Fuel. Because the legitimate concern is under-nutrition during a catabolic event, the practical move is to protect protein intake and lean mass around any healing situation. Clinical-nutrition guidance for surgery emphasizes adequate protein — commonly cited targets sit well above the basic daily allowance, in the range of roughly 1.5 g of protein per kilogram of body weight per day in the recovery period for people who can tolerate it — precisely because protein under-feeding is linked to worse surgical outcomes (Weimann 2017^[9]; Weimann 2024^[10]). On a GLP-1, hitting that target takes deliberate effort, because the whole point of the drug is that you feel less hungry.

Preserving muscle matters for the same reason. Lean mass is both a protein reservoir and a marker of overall resilience; the concern raised in the cardiovascular and metabolic literature is that losing too much muscle during pharmacologic weight loss could blunt recovery and function, which is why “preserve the metabolic engine” — protect muscle — has become a theme in obesity-pharmacotherapy commentary (Sanchis-Gomar 2025^[11]; Neeland 2024^[8]). The two best-supported countermeasures are higher protein intake and resistance (strength) training. For a structured approach, see our GLP-1 muscle-loss prevention protocol.

• Prioritize protein, especially around any procedure or injury. Aim for a high-protein intake (guideline-cited recovery targets are roughly 1.5 g/kg/day for those who tolerate it); spread it across meals. This is the single most actionable lever (Weimann 2017^[9]).
• Keep resistance training in the mix. Strength work helps preserve the lean mass that GLP-1 weight loss can erode, supporting the protein reserve healing draws on (Neeland 2024^[8]; Sanchis-Gomar 2025^[11]).
• Flag poor intake to your team. If GLP-1 nausea, early fullness, or appetite loss is keeping you from eating enough protein around a surgery or wound, tell your prescriber and surgical team — that's the modifiable risk, and they can adjust the plan or add nutrition support.
• Don't stop your GLP-1 on your own for “healing” reasons. Any perioperative hold is a separate decision driven by aspiration/anesthesia guidance, not wound healing — coordinate it with your team (see the surgery/anesthesia article).

Bottom line

The popular claim that GLP-1 drugs impair wound healing is not supported by human evidence. There is no randomized trial showing they slow surgical or skin wound healing, the available human diabetes data show fewer amputations rather than more (Dhatariya 2018^[6]), and laboratory and animal studies actually lean toward benefit through anti-inflammatory and pro-angiogenic effects (Ghebrehiwet-Kuflom 2025^[1]; Nagae 2018^[2]; Huang 2021^[3]; Zhu 2023^[5]; Seo 2017^[4]). The legitimate concern is indirect: rapid weight loss with suppressed appetite can leave you short on the protein a healing wound demands, and can cost you muscle (Neeland 2024^[8]; Wilding 2021^[7]). So the right response is nutritional, not fearful — protect protein intake and lean mass around any procedure or injury (Weimann 2017^[9]; Sanchis-Gomar 2025^[11]), and coordinate perioperative decisions with your prescriber and surgical team.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed study, clinical-nutrition guideline, or narrative review indexed in PubMed, with each PMID verified against the live PubMed database before publication. Discuss your own perioperative and nutrition plan with your prescriber and surgical team.